Disease Modifying Trial Designs and Statistical Analysis
*Chunming M. Li, Pfizer Keywords: Disease modifying drugs development is certainly one of the most challenging areas in terms of design, analysis and registration. In many disease areas (Osteoarthritis and Alzheimer’s disease, for example), such a success would mean great market potential. The roundtable will focus on previous experience, FDA perspective and biomarker applications. Please feel free to bring your case study for group discussion.
|
Key Dates
-
April 30 - May 22, 2013
Invited Abstract Submission Open -
June 4, 2013
Online Registration Opens -
August 9 - August 23, 2013
Invited Abstract Editing -
August 23, 2013
Short Course materials due from Instructors -
August 26, 2013
Housing Deadline -
September 9, 2013
Cancellation Deadline and Registration Closes @ 11:59 pm EDT -
September 16 - September 18, 2013
Marriott Wardman Park, Washington, DC